Patient # Sex Age (yrs) NET foci at baseline PP (pg/ml, <85.8)         Glucagon (pg/ml, 60-209)         NET max diameter (mm)                 baseline +12 m. +24 m. + 48 m. + 72 m. baseline +12 m. +24 m. + 48 m. + 72 m. baseline +12 m. +24 m. + 48 m. +72 m. 1 F 33 Multiple 102 63.8 33.3 35.6 30.8 252 138 82.8 108 156 <10 <10 <10 <10 <10 2 F 30 Single 197 33.3 16.0 28 68 235 127 98 100 110 10 10 10 10 10 3 F 34 Single 116 8.96 5.11 6 4.5 304,2 209 174 135 155 10 10 10 10 10 4 M 34 Multiple 122 72 66.1 70 62.4 41, 5§ 18.2§ 9.9§ 9.5 8.7 12 12 12 12 12 5* M 62 Single 562 NA NA NA NA 362 NA NA NA NA 18 NA NA NA NA 6 M 31 Multiple 451 67.7 108 99 81 352 145 168 152 146 <10 <10 <10 <10 <10 7** F 35 Multiple 98 NA NA NA NA 257 NA NA NA NA 15 NA NA NA NA 8 F 36 Single 202 75.7 37.6 41 33 259 199 166 131 103 17 17 17 17 17

Table 2: Baseline characteristics of the patients enrolled in the LARO-MEN1 study and biochemical and morphological follow-up; *: treatment with Octreotide discontinued at +14 days because of adverse event (diffuse abdominal pain); **: treatment with Octreotide LAR discontinued at 3 months because of the occurrence of insulinoma requiring surgery; §: somatostatin (pg/ml, <37); PP=pancreatic polypeptide; NA=not assessed